title: Quantitation of anacetrapib, stable-isotope labeled-anacetrapib (microdose), and four metabolites in human plasma using liquid chromatography tandem mass spectrometry.
abstract: An ultra-high performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous determination of (4S,5R)-5-[3,5-bis (trifluoromethyl)phenyl]-3-{[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl] methyl}-4-methyl-1,3-oxazolidin-2-one (anacetrapib, I) and [(13)C5(15)N]-anacetrapib, II in human plasma has been developed to support a clinical study to determine the absolute bioavailability of I. The analytes and the stable-isotope labeled internal standard ([(13)C7(15)N(2)H7]-anacetrapib, III) were extracted from 100μL of human plasma by liquid-liquid extraction using 20/80 isopropyl alcohol/hexane (v/v). The chromatographic separation of the analytes was achieved using Waters BEH Shield RP 18 (50×2.1mm×1.7μm) column and mobile phase gradient of 0.1% formic acid in water (Solvent A) and 0.1% formic acid in acetonitrile (Solvent B) at 0.6mL/min flow rate. The MS/MS detection was performed on AB Sciex 5000 or AB 5500 in positive electrospray ionization mode, operated in selected reaction monitoring mode. The assay was validated in the concentration range 1-2000ng/mL for I; and a lower curve range, 0.025-50ng/mL for II. In addition to the absolute bioavailability determination, it was desired to better elucidate the pharmacokinetic behavior of several hydroxylated metabolites of I. Toward this end, two exploratory assays for the hydroxy metabolites of I were qualified in the concentration range 0.5-500ng/mL. All metabolites were separated on a Supelco Ascentis Express Phenyl-Hexyl (50×2.1mm, 2.7μm) column. Metabolite M4 was analyzed in the negative mode with a mobile phase consisting of a gradient mixture of water (A) and acetonitrile (B). The other three metabolites, M1-M3 were analyzed in the positive mode using a mobile phase gradient of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B). The assays were utilized to support a clinical study in which a microdosing approach was used to determine the pharmacokinetics of anacetrapib and its metabolites.
authors.affiliation: Merck Research Laboratories, Kenilworth, NJ, USA. Electronic address: cynthia_chavezeng@merck.com.
authors.forename: C M
authors.initials: CM
authors.lastname: Chavez-Eng
authors.affiliation: Merck Research Laboratories, Kenilworth, NJ, USA.
authors.forename: R W
authors.initials: RW
authors.lastname: Lutz
authors.affiliation: Merck Research Laboratories, Kenilworth, NJ, USA.
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.affiliation: Merck Research Laboratories, Kenilworth, NJ, USA.
authors.forename: D
authors.initials: D
authors.lastname: Goykhman
authors.affiliation: Merck Research Laboratories, Kenilworth, NJ, USA.
authors.forename: K P
authors.initials: KP
authors.lastname: Bateman
authors.affiliation: Merck Research Laboratories, Kenilworth, NJ, USA.
authors.forename: E
authors.initials: E
authors.lastname: Woolf
mesh_terms: D001682:Biological Availability; D002853:Chromatography, Liquid / Q000379:methods*; D006801:Humans; D007553:Isotope Labeling; D016014:Linear Models; D023303:Oxazolidinones / Q000097:blood* / Q000737:chemistry / Q000493:pharmacokinetics*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D053719:Tandem Mass Spectrometry / Q000379:methods*
chemical_list: D023303:Oxazolidinones; C530884:anacetrapib
keywords: Anacetrapib; Bioavailability; Metabolites; Microdosing; UPLC–MS/MS